控制体内血糖水平是成功治疗许多疾病的关键，如糖尿病。 因此， Novo Nordisk公司正在寻找新的小分子，它可以于D-葡萄糖的生理集合密切结合 (持续的取代，Kd，低毫摩尔范围)
悬赏须提交概念性实验数据报告和样品，Novo Nordisk公司将决定最终得奖者，并颁发起始奖金200000美金。
另外Novo Nordisk公司将提议基于里程碑式的合约，如果分子式在未来悬赏中得到成功研发，将会得到二次奖项。
悬赏截止时期2017年1月9日,
投标网址：https://www.innocentive.com/ar/projectRoom/index?challenge=9933823
原文:
Novo Nordisk Challenge: Design and Synthesis of a Small Molecule Glucose Binder
TAGS:
Chemistry, Life Sciences, Royal Society of Chemistry, RTP
AWARD: $200,000 USD | DEADLINE: 1/09/17 | ACTIVE SOLVERS: 145 | POSTED: 3/30/16
The control of glucose levels in the body is key for successful treatment of many disease states such as diabetes. Hence, Novo Nordisk is looking for novel small molecules that can bind with affinities matching the physiological concentrations of D-glucose (displacement constant, Kd, in the low millimolar range).
This is a Reduction-to-Practice Challenge that requires written documentation, experimental proof-of-concept data, and sample delivery. Additionally, the Challenge has the following unique features.Please read carefully the Challenge-Specific Agreement.
• Solvers are asked to prepare the compound and perform binding affinity assays to glucose in aqueous solution under conditions described in the Challenge Description. The compounds must also be supplied to Novo Nordisk in sufficient amounts to reproduce the results. Upon experimental validation of the results, Novo Nordisk will make an award (‘Initial Transfer Fee’) of $200,000 to the best solution as solely determined by the Seeker, according to the Challenge requirements. The Awarded Solver grants Novo Nordisk an exclusive license under the terms described in the Challenge-Specific Agreement.
• Additionally, Novo Nordisk will offer a milestone-based agreement to the Solver, establishing the terms of payment of anadditional award (‘Secondary Award’), should the small molecule be successful in its development post-Challenge(‘Second Evaluation Period’), in exchange
[更多]
